HK1147736A1 - Improved processes for making hydrazides - Google Patents

Improved processes for making hydrazides

Info

Publication number
HK1147736A1
HK1147736A1 HK11101744.4A HK11101744A HK1147736A1 HK 1147736 A1 HK1147736 A1 HK 1147736A1 HK 11101744 A HK11101744 A HK 11101744A HK 1147736 A1 HK1147736 A1 HK 1147736A1
Authority
HK
Hong Kong
Prior art keywords
improved processes
hydrazides
making
making hydrazides
processes
Prior art date
Application number
HK11101744.4A
Other languages
English (en)
Inventor
George A Chiarello
Ayman Sahli
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of HK1147736A1 publication Critical patent/HK1147736A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/48—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/04—Preparation of hydrazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
    • C07C319/12—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols by reactions not involving the formation of mercapto groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coating Apparatus (AREA)
HK11101744.4A 2007-05-22 2011-02-23 Improved processes for making hydrazides HK1147736A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93952907P 2007-05-22 2007-05-22
PCT/US2008/064213 WO2008147765A1 (en) 2007-05-22 2008-05-20 Improved processes for making hydrazides

Publications (1)

Publication Number Publication Date
HK1147736A1 true HK1147736A1 (en) 2011-08-19

Family

ID=39810161

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11101744.4A HK1147736A1 (en) 2007-05-22 2011-02-23 Improved processes for making hydrazides
HK12112795.8A HK1172008A1 (zh) 2007-05-22 2012-12-11 製造酰肼的改良方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12112795.8A HK1172008A1 (zh) 2007-05-22 2012-12-11 製造酰肼的改良方法

Country Status (25)

Country Link
US (5) US8110705B2 (zh)
EP (2) EP2465541B1 (zh)
JP (4) JP5697446B2 (zh)
KR (1) KR101547705B1 (zh)
CN (2) CN102558001B (zh)
AR (1) AR066674A1 (zh)
AU (1) AU2008256905B2 (zh)
BR (1) BRPI0811140B1 (zh)
CA (1) CA2687852A1 (zh)
CL (1) CL2008001490A1 (zh)
CY (2) CY1119373T1 (zh)
DK (2) DK2465541T3 (zh)
ES (2) ES2642888T3 (zh)
HK (2) HK1147736A1 (zh)
HU (2) HUE036704T2 (zh)
IL (1) IL202242A (zh)
MX (1) MX2009012587A (zh)
PA (1) PA8781201A1 (zh)
PE (1) PE20090305A1 (zh)
PL (2) PL2155258T3 (zh)
PT (2) PT2155258T (zh)
SI (2) SI2465541T1 (zh)
TW (1) TW200904784A (zh)
WO (1) WO2008147765A1 (zh)
ZA (1) ZA200908229B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558001B (zh) * 2007-05-22 2015-09-23 惠氏有限责任公司 制造酰肼的改良方法
ES2768611T3 (es) * 2013-11-04 2020-06-23 Pfizer Intermedios y procedimientos para sintetizar derivados de calicheamicina
TW201605480A (zh) 2013-11-04 2016-02-16 輝瑞大藥廠 抗ｅｆｎａ４抗體－藥物結合物
SG10201809628SA (en) 2014-04-30 2018-11-29 Pfizer Anti-ptk7 antibody-drug conjugates
US10135670B2 (en) * 2014-12-22 2018-11-20 Hewlett Packard Enterprise Development Lp Response to an inoperative network device managed by a controller
WO2019018647A1 (en) 2017-07-20 2019-01-24 Pfizer Inc. ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
US20200318053A1 (en) 2017-10-03 2020-10-08 University Public Corporation Osaka Cell culture container, method for acquiring cells, and method for culturing cells
CN109574870A (zh) * 2018-12-25 2019-04-05 维思普新材料（苏州）有限公司 一种酰肼的连续制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US623230A (en) * 1899-04-18 Rotary ore-cooler
DE2608336A1 (de) 1975-03-11 1976-09-30 Sandoz Ag Neue organische verbindungen, ihre herstellung und verwendung
US4291022A (en) * 1975-03-11 1981-09-22 Sandoz Ltd. Organic compounds
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4479953A (en) * 1983-08-25 1984-10-30 Merck & Co., Inc. Pyrazine aldimine compounds as antimicrobial agents
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4729781A (en) * 1986-08-04 1988-03-08 Sandoz Ltd. 3,6-dichloro-2-methoxybenzohydroxamic acid derivatives and use as herbicidal agents
DE3771413D1 (de) * 1986-08-04 1991-08-22 Sandoz Ag Benzhydroxamsaeure-derivate.
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US4939244A (en) 1987-01-30 1990-07-03 American Cyanamid Company Pseudoaglycones of LL-E33288 antibiotics
US5053394A (en) * 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
JPH05222044A (ja) * 1991-10-25 1993-08-31 Eastman Kodak Co ２当量ピラゾロトリアゾールマゼンタカプラーの製造
KR100235246B1 (ko) * 1991-11-22 1999-12-15 아이.제이.크라코워 살충제 페닐히드라진 유도체
US5690904A (en) * 1993-07-12 1997-11-25 Amersham International Plc Diagnostic radiopharmaceutical compounds (That)
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5403015A (en) * 1993-12-09 1995-04-04 Forte; Steven L. Cards and methods for playing casino 21 or blackjack
AU3264695A (en) * 1994-08-23 1996-03-14 Nissan Chemical Industries Ltd. Pyridine derivative
IT1292092B1 (it) 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
DE69936998T2 (de) * 1998-10-16 2008-05-21 Merck Sharp & Dohme Ltd., Hoddesdon Pyrazolotriazinderivate als gaba-rezeptorliganden
GB0008696D0 (en) * 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic agents
IL159086A0 (en) 2001-06-08 2004-05-12 Cytovia Inc 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same
PL224001B1 (pl) * 2002-05-02 2016-11-30 Wyeth Corp Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie
US6803379B2 (en) * 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
US7144876B2 (en) * 2002-12-18 2006-12-05 Cytovia, Inc. 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
ATE441417T1 (de) 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7812016B2 (en) 2003-05-13 2010-10-12 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
MXPA06000276A (es) 2003-07-02 2006-04-07 Sugen Inc Indolinona hidrazidas como inhibidores de c-met.
EP1638955A2 (en) 2003-07-02 2006-03-29 Vertex Pharmaceuticals Incorporated Pyrimidines useful as modulators of voltage-gated ion channels
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US20070203098A1 (en) * 2004-04-06 2007-08-30 Semafore Pharmaceuticals, Inc. Pten Inhibitors
AR052774A1 (es) * 2004-10-08 2007-04-04 Wyeth Corp Inmunoterapia para trastornos autoinmunes
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
CN102558001B (zh) * 2007-05-22 2015-09-23 惠氏有限责任公司 制造酰肼的改良方法

Also Published As

Publication number Publication date
AR066674A1 (es) 2009-09-02
US20120130052A1 (en) 2012-05-24
JP2016026219A (ja) 2016-02-12
EP2465541B1 (en) 2018-07-18
KR20100031514A (ko) 2010-03-22
MX2009012587A (es) 2010-05-14
HUE036704T2 (hu) 2018-07-30
EP2155258A1 (en) 2010-02-24
AU2008256905A1 (en) 2008-12-04
HK1172008A1 (zh) 2013-04-12
US8110705B2 (en) 2012-02-07
JP2010528031A (ja) 2010-08-19
US8853451B2 (en) 2014-10-07
BRPI0811140A2 (pt) 2015-10-27
US8383857B2 (en) 2013-02-26
PL2465541T3 (pl) 2018-12-31
IL202242A (en) 2016-03-31
EP2155258B1 (en) 2017-08-16
ES2686019T3 (es) 2018-10-16
RU2009143524A (ru) 2011-06-27
PT2465541T (pt) 2018-10-17
CN102558001A (zh) 2012-07-11
ZA200908229B (en) 2010-08-25
JP2013234203A (ja) 2013-11-21
IL202242A0 (en) 2010-06-16
DK2155258T3 (en) 2017-09-18
CN101835494B (zh) 2012-02-15
KR101547705B1 (ko) 2015-08-26
PL2155258T3 (pl) 2017-12-29
JP2017193584A (ja) 2017-10-26
SI2155258T1 (sl) 2017-10-30
WO2008147765A1 (en) 2008-12-04
US20080312422A1 (en) 2008-12-18
TW200904784A (en) 2009-02-01
JP5697446B2 (ja) 2015-04-08
EP2465541A1 (en) 2012-06-20
US20130211053A1 (en) 2013-08-15
CL2008001490A1 (es) 2008-07-25
HUE039657T2 (hu) 2019-01-28
US20150099865A1 (en) 2015-04-09
PT2155258T (pt) 2017-10-18
PA8781201A1 (es) 2008-12-18
ES2642888T3 (es) 2017-11-20
CA2687852A1 (en) 2008-12-04
CN102558001B (zh) 2015-09-23
US9738602B2 (en) 2017-08-22
DK2465541T3 (en) 2018-09-17
US9227924B2 (en) 2016-01-05
PE20090305A1 (es) 2009-03-15
CY1119373T1 (el) 2018-02-14
US20160176809A1 (en) 2016-06-23
CY1120592T1 (el) 2019-12-11
BRPI0811140B1 (pt) 2022-08-16
SI2465541T1 (sl) 2018-10-30
AU2008256905B2 (en) 2014-05-08
CN101835494A (zh) 2010-09-15

Similar Documents

Publication Publication Date Title
GB0715101D0 (en) Process
GB0711624D0 (en) Process
EP2123631A4 (en) PROCESS FOR THE PREPARATION OF ALKOXYPROPIONAMIDE
GB0706978D0 (en) Process
GB0700074D0 (en) process
GB0716126D0 (en) Process
EP2152631A4 (en) NICKEL LATERITE PROCEDURE
HK1172008A1 (zh) 製造酰肼的改良方法
GB0711680D0 (en) Process
GB0714602D0 (en) Process
GB0714390D0 (en) Process
PL2173197T3 (pl) Sposób
GB0700878D0 (en) Process
GB201003018D0 (en) Process
GB0724716D0 (en) Process
GB0724232D0 (en) Process
PL2152091T5 (pl) Sposób
GB0719251D0 (en) Process
GB0701966D0 (en) Process
GB0722073D0 (en) Process
GB0707287D0 (en) Process
GB0709695D0 (en) Process
GB0705648D0 (en) Process
GB0705647D0 (en) Process
GB0720119D0 (en) Process